Antipsychotic drugs have been the primary
psychopharmacological mainstay of treatment
for psychosis, agitation, and aggression in
Alzheimer Disease (AD) and other dementias.
Conventional antipsychotic drugs such as haloperidol have been supplanted by newer, atypical antipsychotics (risperidone [Risperdal], olanzapine [Zyprexa], quetiapine [Seroquel], ziprasidone [Geodon], aripiprazole [Abilify]), although no medication has an FDA indication for the treatment of behavioral symptoms in patients with dementia.1-5
During the past 3 years, a number of placebo-controlled clinical trials of atypical antipsychotics for behavioral symptoms have reported small treatment effect sizes coupled with adverse effects at rates that exceed those observed in placebo-treated patients.6,7 Results from some prospective randomized controlled trials of dementia and subsequent meta-analyses suggest that atypical antipsychotic pharmacotherapy is associated with an increased risk of mortal-ity and cerebrovascular adverse events (CVAEs).8,9 These developments have fueled an ongoing debate over the appropriate prescribing of antipsychotics.9-11
Widespread acceptance of atypical antipsychotics for psychosis and behavioral symptoms preceded the availability of a supportive evidence base. In light of ongoing controversies and recently published data, it is essential that clinicians understand the most current information about the use of atypical antipsychotics in patients with dementia.
Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) was the first head-to-head, prospective, randomized, double-blind, placebo-controlled effectiveness study of atypical antipsychotic therapy in AD.7 The unique design measured outcomes associated with real-world prescribing of these medications to treat behavioral symptoms. The goal of the study was to determine the effectiveness and tolerability of 3 atypical antipsychotics (compared with placebo) in the treatment of dementia-related behavioral symptoms in patients residing in community settings. The multicenter trial was funded by the National Institute of Mental Health.
In the initial, 36-week phase of the study, outpatients with mild to severe AD and behavioral symptoms (delusions, hallucinations, aggression, agitation) of at least moderate severity were randomly selected to receive flexible dosing with olanzapine (n = 100), risperidone (n = 85), quetiapine (n = 94), or placebo (n = 142). (Aripiprazole and ziprasidone were not included in the study because they were not available in the United States at the time the trial was designed.)
The study population was moderately cognitively impaired (Mini-Mental State Examination score, 15 ± 5.8). The mean age was 77.9 ± 7.5 years. Baseline behavioral symptoms were of moderate severity (Neuropsychiatric Inventory score, 36.9 ± 18.3), and 60% of the study participants received adjunctive acetylcholinesterase inhibitor therapy at study entry.
Participants who responded adequately to therapy could continue the trial up to 36 weeks. If the physician determined that response was inadequate for any reason after the initial 2 weeks of therapy, treatment was discontinued. Patients whose therapy was discontinued could enter phase 2 of the trial wherein they would be randomly selected to receive one of the other antipsychotics or citalopram under double-blind conditions. Only phase 1 data have been published at this time.
The primary outcome was time to discontinuation of treatment for any reason in phase 1 of the study. In this study design, "time to discontinuation" was a composite outcome that incorporated the combined effects of efficacy, tolerability, and caregiver burden for each treatment condition.
1. Daniel DG. Antipsychotic treatment of psychosis
and agitation in the elderly. J Clin Psychiatry.
2. Franco KN, Messinger-Rapport B. Pharmacological
treatment of neuropsychiatric symptoms
of dementia: a review of the evidence. J Am Med
Dir Assoc. 2006;7:201-202.
3. Lane HY, Chang YC, Su MH, et al. Shifting
from haloperidol to risperidone for behavioral
disturbances in dementia: safety, response predictors,
and mood effects. J Clin Psychopharmacol.
4. Sultzer DL. Psychosis and antipsychotic medications
in Alzheimer’s disease: clinical management
and research perspectives. Dement Geriatr
Cogn Disord. 2004;17:78-90.
5. Wang PS, Brookhart MA, Setoguchi S, et al.
Psychotropic medication use for behavioral
symptoms of dementia. Curr Neurol Neurosci Rep.
6. Ballard C, Waite J. The effectiveness of atypical
antipsychotics for the treatment of aggression and
psychosis in Alzheimer’s disease. Cochrane Database
Syst Rev. 2006(1):CD003476.
7. Schneider LS, Tariot PN, Dagerman KS, et al.
Effectiveness of atypical antipsychotic drugs in
patients with Alzheimer’s disease. N Engl J Med.
8. Brodaty H, Ames D, Snowdon J, et al. A randomized
placebo-controlled trial of risperidone
for the treatment of aggression, agitation, and
psychosis of dementia. J Clin Psychiatry. 2003;64:
9. Schneider LS, Dagerman KS, Insel P. Risk of
death with atypical antipsychotic drug treatment
for dementia: meta-analysis of randomized placebo-
controlled trials. JAMA. 2005;294:1934-1943.
10. Brodaty H, Ames D, Snowdon J, et al.
Risperidone for psychosis of Alzheimer’s disease
and mixed dementia: results of a double-blind,
placebo-controlled trial. Int J Geriatr Psychiatry.
11. Kryzhanovskaya LA, Jeste DV, Young CA, et
al. A review of treatment-emergent adverse
events during olanzapine clinical trials in elderly
patients with dementia. J Clin Psychiatry. 2006;67:
12. Katz IR, Jeste DV, Mintzer JE, et al. Comparison
of risperidone and placebo for psychosis and
behavioral disturbances associated with dementia:
a randomized, double-blind trial. Risperidone
Study Group. J Clin Psychiatry. 1999;60:107-115.
13. Street JS, Clark WS, Gannon KS, et al. Olanzapine
treatment of psychotic and behavioral
symptoms in patients with Alzheimer disease in
nursing care facilities: a double-blind, randomized,
placebo-controlled trial. The HGEU Study
Group. Arch Gen Psychiatry. 2000;57:968-976.
14. Zhong KX, Tariot PN, Mintzer J, et al. Quetiapine
to treat agitation in dementia: a randomized,
double-blind, placebo-controlled study. Curr
Alzheimer Res. 2007;4:81-93.
15. Newcomer JW. Metabolic considerations in
the use of antipsychotic medications: a review of
recent evidence. J Clin Psychiatry. 2007;68(suppl
16. Lieberman JA, Stroup TS, McEvoy JP, et al.
Effectiveness of antipsychotic drugs in patients
with chronic schizophrenia. N Engl J Med. 2005;
17. Nasrallah HA. Metabolic findings from the
CATIE trial and their relation to tolerability. CNS
Spectr. 2006;11(7, suppl 7):32-39.
18. Shekelle P, Manglione M, Bagley S, et al.
Comparative Effectiveness of Off-Label Use of
Atypical Antipsychotics. Available at: http://effectivehealthcare.ahrq.gov/reports/topic.cfm?topic=8sid=34&rType=3. Accessed July 2, 2007.
19. Schneider LS, Dagerman K, Insel PS. Efficacy
and adverse effects of atypical antipsychotics for
dementia: meta-analysis of randomized, placebocontrolled
trials. Am J Geriatr Psychiatry. 2006;14:
20. Recupero PR, Rainey SE. Managing risk
when considering the use of atypical antipsychotics
for elderly patients with dementia-related
psychosis. J Psychiatr Pract. 2007;13:143-152.
21. Wang PS, Schneeweiss S, Avorn J, et al. Risk
of death in elderly users of conventional vs atypical
antipsychotic medications. N Engl J Med.
22. Schneeweiss S, Setoguchi S, Brookhart A, et
al. Risk of death associated with the use of conventional
versus atypical antipsychotic drugs
among elderly patients. CMAJ. 2007;176:627-632.
23. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic
drug use and mortality in older adults
with dementia. Ann Intern Med. 2007;146:775-786.
24. Treatment of dementia and agitation: a guide
for families and caregivers. J Psychiatr Pract. 2007;